Medtech R&D departments appear to be on the same page as patients.

An analysis from McKinsey and the Institute for Health Metrics and Evaluation (IHME) shows how top medtech innovation pipelines line up closely with unmet health needs—from oncology to dental disease. This is good news. But it leaves us wondering how these pipelines are panning out when it comes to approvals and patient access. After all, R&D isn’t the end of the road for direly-needed medtech products.